Regulatory Roundup: EMEA Reaffirms Efficacy of Two H1N1 Vaccines
ePT--the Electronic Newsletter of Pharmaceutical Technology
The European Medicines Agency confirmed the safety and efficacy of Focetria and Pandermix, and noted that data on Celvapan are still being analyzed.
The European Medicines Agency (EMEA) released a statement reaffirming the efficacy and safety of the influenza A (H1N1) vaccines Focetria (Novartis, Basel) and Pandemrix (GlaxoSmithKline, London) after the agency had comducted further data review. EMEA indicated that a single dose of these vaccines is able to trigger an immune response against H1N1 in adults aged 18 and 60 and in children and adolescents (from the age of 9 years for Focetria, and from 10 years for Pandemrix). Pandemrix may also be used as a single dose in the elderly. For younger children and people with compromised immune systems, EMEA recommends that two doses be given for an adequate immune response. EMEA said that data on Celvapan (Baxter, Deerfield, IL) are still being assessed. The agency also stated that Focetria and Pandemrix can be co-administered with nonadjuvanted seasonal flu vaccines.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
